Milrinone (Lactate)
Milrinone (Lactate) Information

About Milrinone (Lactate)

Milrinone (Lactate) is a phosphodiesterase III inhibitor similar to amrinone, with +ve ionotropic and vasodilator activity. It potentiate effects of cyclic adenosine monophosphate(cAMP). Milrinone (Lactate) is administered intravenosly in the management of heart failure(severe) unresponsive to other form & in acute heart failure after cardiac surgery.

Indications

Milrinone (Lactate) is primarily indicated in conditions like Acute heart failure, Congestive heart failure, Heart failure, Short-term treatment of severe congestive heart failure, Tobacco amblyopia and leber's optic atrophy.

Contraindication

Milrinone (Lactate) is contraindicated in conditions like Allergy,Hypotension,Ventricular arrhythmias,Hypersensitivity,Pregnancy,Supraventricular arrhythmias,Prophylaxis of mycobacterium avium complex infections.

Side Effects

The severe or irreversible adverse effects of Milrinone (Lactate), which give rise to further complications include Hypotension, Bronchospasm, Hypotension, Bronchospasm, Angina, Anaphylaxis, Supraventricular arrhythmia, Ventricular arrhythmia.Milrinone (Lactate) produces potentially life-threatening effects which include Arrhythmias, Hypotension. which are responsible for the discontinuation of Milrinone (Lactate) therapy.The symptomatic adverse reactions produced by Milrinone (Lactate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Palpitation, Rashes, Hypotension, Somnolence, Tremor, Thrombocytopenia, Hypokalemia, Angina.

Warnings

Blood pressure, heart rate, ECG, fluid and electrolyte balance should be monitored during therapy. It should be used with caution in patients with severe obstructive aortic or pulmonary valvular disease or with hypertrophic cardiomyopathy and in children and in patients with decreased renal function,hypokalemia,hypotension.

High Risk Groups

Drug should not be given to Paediatrics, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.